Skip to main content

Galectin Therapeutics Inc

GALT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001133416

No open-market purchases or sales by Galectin Therapeutics Inc insiders were filed in the last 90 days; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 16, 2026
$304.6M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, 0 vs. previous quarter
98
13F valueReported value at the end of Q2 2026
$72.2M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$30.8M
No comparable prior period
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q2 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
8.98M
Shares sold short
Change
−154.6K
−1.7% vs. previous
Days to cover
46.26
At average daily volume

Superinvestors holding GALT, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding GALT at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Galectin Therapeutics Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 16, 2026 (view filing)5:39 PM ETJul 142 daysJamil KhurramChief Medical OfficerSSale−16.3K$5.13−$83.3K−100.0%0 after10b5-1
Jun 30, 2026 (view filing)Jun 26-294 daysShlevin Harold H.DirectorSSale−30.0K$5.03−$150.9K−82.2%6.50K after2 lots10b5-1
Jun 30, 2026 (view filing)Jun 26-294 daysJamil KhurramChief Medical OfficerSSale−52.0K$5.04−$262.1K−100.0%0 after3 lots10b5-1
Jun 25, 2026 (view filing)Jun 232 daysJamil KhurramChief Medical OfficerSSale−7.56K$3.14−$23.7K−100.0%0 after10b5-1
May 28, 2026 (view filing)May 262 daysJamil KhurramChief Medical OfficerSSale−568$3.10−$1.76K−100.0%0 after10b5-1
Feb 9, 2026 (view filing)Feb 63 daysEldred KaryDirectorPPurchase+300$2.70+$810+0.5%65.7K after
Jan 6, 2026 (view filing)Jan 2-64 daysLewis JoelPresident and CEOSSale−84.0K$3.83−$321.4K−9.2%832.6K after3 lots10b5-1
Jan 6, 2026 (view filing)Jan 2-64 daysCallicutt Jack WChief Financial OfficerSSale−60.0K$3.89−$233.5K−88.7%7.61K after3 lots10b5-1
Jan 6, 2026 (view filing)Jan 2-64 daysJamil KhurramChief Medical OfficerSSale−34.5K$3.86−$133.1K−100.0%0 after2 lots10b5-1
Jan 6, 2026 (view filing)Jan 51 dayJamil KhurramChief Medical OfficerSSale−25.5K$3.90−$99.4K−54.3%21.4K after10b5-1

Top 10 13F holders, Q2 2026

See all 98 holders

The largest institutional positions in Galectin Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding GALT in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.2,988,353$13.9M0.00%+2,189,116+273.9%Added
Vanguard Capital Management LLC2,168,065$10.1M0.00%+201,523+10.2%Added
Geode Capital Management, LLC1,308,394$6.07M0.00%+695,608+113.5%Added
Advisor Group Holdings, Inc.1,203,725$5.59M0.01%+81,055+7.2%Added
Marshall Wace, LLP831,010$3.86M0.00%−388,902−31.9%Reduced
Wealthspire Advisors, LLC721,788$3.35M0.02%00.0%Unchanged
State Street Corp567,779$2.63M0.00%+309,347+119.7%Added
Commonwealth Equity Services, LLC407,113$1.89M0.00%+40,000+10.9%Added
Northern Trust Corp386,545$1.79M0.00%+256,097+196.3%Added
Vanguard Fiduciary Trust Co366,476$1.70M0.00%+62,235+20.5%Added

Holders of 5% or more of GALT

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Galectin Therapeutics Inc.

Largest holders of GALT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Uihlein Richard E13D/A49.30%54.7M shares–Aug 4, 20261 filingAug 4, 2026SEC